Effects of Parenteral Nutrition on the Exocrine Pancreas in Response to Cholecystokinin

Abstract

Background: Clinical and experimental data have revealed that parenteral nutrition (PN) can lead to hypotrophy and dysfunction in the morphology and physiology of the pancreas. These adverse alterations appear to be related to many different factors. One important factor is the absence of a gastrointestinal hormone, such as cholecystokinin, which is the most important stimulator for the integrity of the pancreas. The level of cholecystokinin is decreased during absent enteral feeding, and the stimulatory effect of cholecystokinin is significantly reduced during PN. Methods: Original and review articles, editorials, and case reports published primarily in English and listed in MEDLINE/ISI up to September 2006 or identified by a manual search have been reviewed in an attempt to provide a comprehensive overview of the effects of PN on the exocrine pancreas in response to cholecystokinin. Results: When hypercholecystokininemia, produced by endogenous and exogenous procedures, is present during PN, the morphology and functions of the pancreas are still unable to be fully reversed. Conclusions: Other growth factors besides cholecystokinin are probably involved in the pancreatic regulation, and enteral feeding seems to be important for the full expression of the trophic effects of cholecystokinin on the pancreas.

Cholecystokinin is a main stimulator of the pancreas, but its stimulatory effect on exocrine pancreas is decreased during long-term parenteral nutrition. This may be due to other factors besides cholecystokinin that are regulated in the exocrine pancreas during parenteral feeding.

Get full access to this article

View all access options for this article.

References

Dudrick SJ, Wilmore DW, Vars HM. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance.Surgery. 1968;64:134– 142.

Meguid MM, Muscaritoli M. Current use of total parenteral nutrition. Am Fam Physician. 1993 ;47:383– 394.

Pisters PW, Ranson JH. Nutritional support for acute pancreatitis.Surg Gyn Obstet. 1992;175:275– 284.

Jognson LR, Larry MS, Stanley JD. Effect of long-term parenteral feeding on pancreatic secretion and serum secretin. Am J Physiol. 1977;233:E524– E529.

Ekelund M, Ekelund M, Qader SS, Hallen M, Ekblad E. Effects of total parenteral nutrition on rat enteric nervous system, intestinal morphology, and motility. J Surg Res. 2005 ;124:187– 193.

Yang H, Finaly R, Teitelbaum DH. Alteration in epithelial permeability and ion transport in a mouse model of total parenteral nutrition.Crit Care Med. 2003;31:1118– 1125.

Mok KT, Meng HC. Intestinal, pancreatic and hepatic effects of gastrointestinal hormones in a total parenteral nutrition rat model.JPEN J Parenter Enteral Nutr. 1993 ;17:364– 369.

Kansagra K, Stoll B, Rognerud C, et al. Total parenteral nutrition adversely affects gut barrier function in neonatal piglets. Am J Physiol Gastrointest Liver Physiol. 2003 ;285:G1162– G1170.

Der Hulst RR, Von Meyenfeldt MF, Kreel BK, et al. Gut permeability, intestinal morphology, and nutritional depletion. Nutrition. 1998 ;14:1– 6.

10.

Perides G, Sharma A, Gopal A, et al. Secretin differentially sensitizes rat pancreatic acini to the effects of supramaximal stimulation with caerulein. Am J Physiol Gastrointest Liver Physiol. 2005 ;289:G713– G721.

11.

Burrin DG, Stoll B. Key nutrients and growth factors for the neonatal gastrointestinal tract. Clin Perinatol. 2002 ;29:65– 96.

12.

Gielkens HA, Biggelaar A, Vecht J, Onkenhout W, Lamers CB, Masclee AA. Effect of intravenous amino acids on interdigestive antroduodenal motility and small bowel transit time. Gut. 1999 ;44:240– 245.

13.

Nealon WH, Upp JR, Alxander RW. Intravenous amino acids stimulate human gallbladder emptying and hormone release. Am J Physiol. 1990 ;259:G173– G178.

14.

Teitelbaum DH, Han-Markey T, Schummacher RE. Treatment of parenteral nutrition-associated cholestasis with cholecystokinin-octapeptide.J Pediatr Surg. 1995;30:1082– 1085.

15.

Niebergall-Roth E, Teyssen S, Singer MV. Neurohormonal control of gallbladder motility. Scand J Gastroenterol. 1997 ;32:737– 750.

16.

Tsai S, Strouse PJ, Drongowski RA, Islam S, Teitelbaum DH. Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease.J Pediatr Surg. 2005;40:263– 267.

17.

Teitelbaum DH, Tracy TF, Aouthmany MM, et al. Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics. 2005 ;115:1332– 1340.

18.

Kuntz E, Pinget M, Damge P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats.JOP. 2004;10:464– 475.

19.

Koop I, Koop H, Gerhardt C, Schafmayer A, Arnold R. Do bile acids exert a negative feedback control of cholecystokinin release? Scand J Gastroenterol. 1989;24:315– 320.

20.

Walsh JH. Gastrointestinal hormones. In: Johnson LR, ed.Physiology of the Gastrointestinal Tract. New York, NY: Raven Press; 1987: 181–253.

21.

Joekel CS, Herrington MK, Vanderhool JA, Adrian TE. Postnatal development of circulating cholecystokinin and secretion, pancreatic growth, and exocrine function in guinea pigs. Int J Pancreatol. 1993 ;13:1– 13.

22.

Adler G, Beglinger C, Braum U, et al. Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans.Gastroenterology. 1991;100:537– 543.

23.

Schweiger M, Steffl M, Amselgruber WM. Determination of target cells for cholecystokinin in the porcine pancreas. Ann Anat. 2005 ;187:209– 214.

24.

Gasslander T, Smeds S, Blomquvist L, Ihse I. Proliferative response of different exocrine pancreatic cell types to hormonal stimuli. Scand J Gastroenterol. 1990;25:1103– 1110.

25.

Axelson J, Håkanson R, Ihse I, Lilja I, Fehfeld JF, Sundler F. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364,718 on pancreatic and gastrointestinal growth. Scand J Gastroenterol. 1990 ;25:471– 480.

26.

Nylander AG, Chen D, Ihse I, Rehfeld JF, Hakanson R. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide. Scand J Gastroenterol. 1992 ;27:743– 747.

27.

Ahrén B, Karlsson S. Pancreatic endocrine physiology. In: Clark OH, ed. Textbook of Endocrine Surgery. Philadelphia, PA: W.B. Saunders Company; 1997:562– 575.

28.

Ahrén B, Ar'Rajab A, Böttcher G, Sundler F, Dunning BE. Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets. Cell Tissue Res. 1991 ;264:263– 267.

29.

Ahrén B, Gingerich RL, Havel PJ. Effects of cholecystokinin and glucagon-like peptide I on the secretion of pancreatic polypeptide in mice. Regul Pept. 1995;59:297– 302.

30.

Guimbaud R, Moreau JA, Bouisson M, et al. Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. Pancreas. 1997;14:76– 82.

31.

Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest. 1985;75:1144– 1152.

32.

Fölsch UR, Cantor P, Wilms HM, Schafmayer A, Becker HD, Creutzfeldt W. Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats.Gastroenterology. 1987;92:449– 458.

33.

Song Y, Lee KY, Chang TM, Chey WY. A secretin releasing peptide exists in dog pancreatic juice. Life Sci. 2000 ;25:1307– 1316.

34.

Povoski S, Zhou W, Longnecker DS. Stimulation of in vivo pancreatic growth in the rat is mediated specially by way of cholecystokinin-A receptors. Gastroenterology. 1994 ;107:1135– 1146.

35.

Le Drean G, Huerou-Luron I, Gestin M, et al. Pancreatic secretory response to feeding in the calf: CCK-A receptors, but not CCK-B/gastrin receptors are involved. Can J Physiol Pharmacol. 2000 ;78:813– 819.

36.

Strader AD, Woods SC. Gastrointestinal hormones and food intake.Gastroenterology. 2005;128:175– 191.

37.

Mashako MN, Bernard C, Cezard JP. Effect of total parenteral nutrition, constant rate enteral nutrition, and discontinues oral feeding on plasma cholecystokinin immunoreactivity in children. J Pediatr Gastroenterol Nutr. 1987;6:948– 952.

38.

Axelson J, Fan BG, Ohlsson B, Rehfeld J, Ekelund M, Ihse I. The changes in the rat parotid glands following total parenteral nutrition and pancreatico-biliary diversion are not mediated by cholecystokinin. Int J Pancreatol. 1996;20:109– 118.

39.

Fan BG, Andrén-Sandberg Å. Influence of an intravenous infusion of amino acids and glucose on the pancreatic exocrine in rats.Chin Med J. 2004;117:1659– 1664.

40.

Fan BG, Andrén-Sandberg Å. IV hypertonic glucose stimulates the exocrine pancreas in rat. JPEN J Parenter Enteral Nutr. 2006;30:40– 44.

41.

Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation.Endocrinology. 1990;127:1580– 1589.

42.

Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acids cycle. J Clin Invest. 1994 ;93:870– 876.

43.

Iovanna JL, Dusetti NJ, Cadennas MB. Changes in pancreatic trophism and gene expression during a prolonged fasting period in rats. Int J Pancreatol. 1991;8:177– 186.

44.

Dowling RH, Hosomi M, Stace NH, et al. Hormones and polyamines in intestinal and pancreatic adaptation. Scand J Gastroenterol. 1985 ;20:84– 95.

45.

Haarstad H, Petersen H. Short- and long-term effects of secretin and a cholecystokinin-like peptide on pancreatic growth and synthesis of RNA and polyamines. Scan J Gastroenterol. 1989 ;24:721– 732.

46.

Miyata T, Enrione EB. The effect of total parenteral nutrition on gastrointestinal hormones in rats. JPEN J Parenter Enteral Nutr. 1993;17:417– 421.

47.

Fan BG, Salehi A, Sternby B, et al. Total parenteral nutrition influence both endocrine and exocrine function of rat pancreas.Pancreas. 1997;15:147– 153.

48.

Solomon TE. Physiology of the exocrine pancreas. In: Howard JM, ed.Surgical Diseases of the Pancreas. Philadelphia, PA: Lea & Febiger; 1987: 46–65.

49.

Chey WY, Chang T. Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology. 2001 ;1:320– 335.

50.

Johnson LR. Regulation of gastrointestinal growth. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract. New York, NY: Raven Press; 1981:169– 196.

51.

Longnecker DS. Hormones and pancreatic cancer. Int J Pancreatol. 1991;9:81– 86.

52.

Niebergall-Roth E, Singer MV. Enteropancreatic reflexes mediating the pancreatic enzyme response to nutrients. Auton Neurosci. 2006 ;125:62– 69.

53.

Gautam D, Han SJ, Heard TS, et al. Cholinergic stimulation of amylase secretion from pancreatic acinar cells studied with muscarinic acetylcholine receptor mutant mice. J Pharmacol Exp Ther. 2005 ;313:995– 1002.

54.

Gingras D, Bendayan M. Evaluation of pancreatic amylase mRNA upon cholinergic stimulation of secretion. J Histochem Cytochem. 2005 ;53:93– 103.

55.

Qader SS, Salehi A, Hakanson R, Lundquist I, Ekelund M. Long-term infusion of nutrients (total parenteral nutrition) suppresses circulating ghrelin in food-deprived rats. Regul Pept. 2005 ;131:82– 88.

56.

Chen D, Anderson K, Iovava JL. Effects of hypercholecystokininemia produced by pancreaticobiliary diversion on pancreatic growth and enzyme mRNA levels in starved rats. Scand J Gastroenterol. 1993 ;28:311– 314.

57.

Hara H, Ohyama S, Hira T. Endogenous cholecystokinin plays a role in down-regulation of pancreatic amylase independent of dietary carbohydrate in rats. Regul Pept. 2001 ;99:103– 110.

58.

Kim M, Nozu F, Kusama K, Imawari M. Cholecystokinin stimulates the recruitment of the Src-RhoA-phosphoinositide 3-kinase pathway by Vav-2 downstream of G (alpha13) in pancreatic acini. Biochem Biophys Res Commun. 2006;339:271– 276.

59.

De-Boer SY, Masclee AA, Jebbink MC, Schipper J, Jansen JB, Lamers CB. Effect of intravenous fat on cholecystokinin secretion and gallbladder motility in man. JPEN J Parenter Enteral Nutr. 1992 ;16:16– 19.

60.

Grundfest S, Steiger E, Selinkoff P, Fletcher J. The effect of intravenous fat emulsions in patients with pancreatic fistula. JPEN J Parenter Enteral Nutr. 1980;4:27– 31.

61.

Lee YL, Kwon HY, Park HS. The role of insulin in the interaction of secretin and cholecystokinin in exocrine secretion of the isolated perfused rat pancreas. Pancreas. 1996 ;1:58– 63.

62.

Fan BG, Axelson J, Sternby B, Rehfeld J, Ihse I, Ekelund M. Total parenteral nutrition affects the trophic effect of cholecystokinin on the exocrine pancreas. Scand J Gastroenterol. 1997 ;32:380– 386.

63.

Shulman RJ, Burrin DG. Total parenteral nutrition energy composition affects small intestinal disaccharides activity in the newborn miniature pig. JPEN J Parenter Enteral Nutr. 1991 ;15:560– 563.

64.

Zawalich W, Takuwa N, Takuwa Y. Interactions of cholecystokinin and glucose in rat pancreatic islets. Diabetes. 1987 ;36:426– 433.

65.

Samli KN, McGuire MJ, Newgard CB, Johnston SA, Brown KC. Peptide-mediated targeting of the islets of Langerhans.Diabetes. 2005;54:2103– 2108.

66.

Myojin T, Kitamura N, Hondo E, Baltazar ET, Pearson GT, Yamada J. Immunohistochemical localization of neuropeptides in bovine pancreas.Anat Histol Embryol. 2000 ;29:167– 172.

67.

Willianms JA, Goldfine ID. The insulin-acinar relationship. In: Go VLW, ed. The Pancreas: Biology, Pathology and Disease. 2nd ed. New York, NY: Raven Press; 1993:789– 800.

68.

Krause U, Bertrand L, Maisin L, Rosa M, Hue L. Signaling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur J Biochem. 2002 ;269:3742– 3750.

69.

Swanson KC, Benson JA, Matthews JC, Harmon DL. Pancreatic exocrine secretion and plasma concentration of some gastrointestinal hormones in response to abomasal infusion of starch hydrolyzate and/or casein. J Anim Sci. 2004;82:1781– 1787.

70.

Lenzen S, Schmidt W, Rustenbeck I, Panten U. 2-Ketoglutarate generation in pancreas B-cell mitochondria regulation insulin secretory action of amino acids and 2-keto acids. Biosci Rep. 1986 ;6:163– 169.

71.

Li C, Matter A, Kelly A, et al. Effects of a GTP-insensitive mutation of glutamate dehydrogenase on insulin secretion in transgenic mice.J Biol Chem. 2006;281:15064– 15072.

72.

Zawalich WS, Yamazaki H, Zawalich KC, Cline G. Comparative effects of amino acids and glucose on insulin secretion from isolated rat or mouse islets. J Endocrinol. 2004 ;183:309– 319.

73.

Li C, Buettger C, Kwagh J, et al. A signaling role of glutamine in insulin secretion. J Biol Chem. 2004 ;279:13393– 13401.

74.

Stratton RJ, Smith TR. Role of enteral and parenteral nutrition in the patient with gastrointestinal and liver disease. Best Pract Res Clin Gastroenterol. 2006;20:441– 466.

75.

Kraft MD, Btaiche IF, Sacks GS. Review of the refeeding syndromes.Nutr Clin Pract. 2005;20:625– 633.

76.

Baudouin SV, Evans TW. Nutritional support in critical care.Clin Chest Med. 2003;24:633– 644.

77.

De Sousa DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med. 2005;33:1125– 1135.

78.

Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R. Glutamine and glutamate: their central role in cell metabolism and function. Cell Biochem Funct. 2003;21:1– 9.

79.

Tsuchioka T, Fujiwara T, Sunagawa M. Effects of glutamic acid and taurine on total parenteral nutrition. J Pediatr Surg. 2006 ;41:1566– 1572.

80.

Gianotti L, Alexander JW, Gennari R, et al. Oral glutamine decreases bacterial translocation and improves survival in experimental gut-origin sepsis. JPEN J Parenter Enteral Nutr. 1995 ;19:69– 74.

81.

Souba WW, Klimberg VS, Plumley DA, et al. The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection. J Surg Res. 1990 ;48:383– 391.

82.

O'Dwyer ST, Smith RJ, Hwang TL, et al. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13:579– 585.

83.

Déchelotte P, Hasselmann M, Cynober L, et al. L-alanyl-L-glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French Controlled, Randomized, Double-Blind, Multicenter Study.Crit Care Med. 2006;34:598– 604.